Effect of oral administration of Butyrivibrio fibrisolvens MDT-1 on experimental enterocolitis in mice
Effect of oral administration of Butyrivibrio fibrisolvens MDT-1 on experimental enterocolitis in mice
复制标题
DOI：
10.1128/cvi.00267-06
复制
发表时间：
2006-11-01
影响因子：
--
通讯作者：
Hino, Tsuneo
中科院分区：
文献类型：
--
作者：
Ohkawara, Sou;Furuya, Hideki;Hino, Tsuneo
Butyrivibrio fibrisolvens MDT-1（一种产生丁酸盐的菌株）被评估用作预防小肠结肠炎的益生菌。口服MDT-1菌株（10（9）CFU/剂）可缓解小鼠饮用含有3.0%葡聚糖硫酸钠的水诱发的结肠炎症状（包括体重减轻、腹泻、血便、器质性病变和粘膜损伤）。此外，结肠组织中的髓过氧化物酶 (MPO) 活性水平降低，表明 MDT-1 可以减轻肠道炎症。添加 MDT-1 培养物上清液抑制了九种可能引起小肠结肠炎的空肠弯曲杆菌和大肠杆菌临床分离株的生长。小鼠感染大肠杆菌 11580-3（MDT-1 体外抑制的分离株之一）会导致腹泻、粘膜损伤、结肠组织中 MPO 活性水平增加、盲肠中大肠杆菌数量增加以及体重增加减少。然而，在大肠杆菌感染之前和期间给小鼠施用 MDT-1 可以减少这些影响。这些结果表明，使用溶纤维芽孢杆菌作为益生菌可以缓解弯曲杆菌诱导的小肠结肠炎。
Butyrivibrio fibrisolvens MDT-1, a butyrate-producing strain, was evaluated for use as a probiotic to prevent enterocolitis. Oral administration of the MDT-1 strain (10(9) CFU/dose) alleviated the symptoms of colitis (including body weight loss, diarrhea, bloody stool, organic disorder, and mucosal damage) that are induced in mice drinking water that contains 3.0% dextran sulfate sodium. In addition, myeloperoxidase (MPO) activity levels in colonic tissue were reduced, suggesting that MDT-1 mitigates bowel inflammation. The addition of MDT-1 culture supernatant inhibited the growth of nine clinical isolates of Campylobacter jejuni and Campylobacter coli that could potentially cause enterocolitis. Infection of mice with C. coli 11580-3, one of the isolates inhibited by MDT-1 in vitro, resulted in diarrhea, mucosal damage, increased MPO activity levels in colonic tissue, increased numbers of C. coli in the cecum, and decreased body weight gain. However, administration of MDT-1 to mice, prior to and during C. coli infection, reduced these effects. These results suggest that Campylobacter-induced enterocolitis can be alleviated by using B. fibrisolvens as a probiotic.